Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock ...

Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...

BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has better results at a lower cost. But it claims rivals are using questionable ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Pfizer PFE announced a definitive agreement to acquire obesity drug developer, Metsera MTSR, to re-enter the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss ...